Nasal Glucagon: A Technical Pros and Cons Analysis
Title: Nasal Glucagon: A Technical Pros and Cons Analysis Abstract: Nasal glucagon (NG) offers a needle-free alternative for severe hypoglycemia, leveraging intranasal peptide delivery to bypass injection barriers. Compared to injectable glucagon, NG demonstrates comparable efficacy (plasma glucose increase 70 mg/dL within 30 min) with superior ease-of-use (single-step administration). However, its higher cost (2–3× vs. injectables) and shorter shelf-life (24 months vs. 36 months) limit adoption. Market trends show a 12.4% CAGR (2023–2030) driven by diabetes prevalence and patient preference. Leading brands (Baqsimi vs. Gvoke) differ in formulation stability and device design. Regulatory approvals (FDA, EMA) ensure safety, but cold-chain logistics remain critical for peptide integrity. NG’s pros (convenience, no reconstitution) outweigh cons (cost, storage) for emergency use, aligning with industry shifts toward patient-centric delivery systems.